Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation by Liu, Xiaming et al.
Protein phosphatase 1
suppresses androgen receptor
ubiquitylation and degradation
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Liu, X., W. Han, S. Gulla, N. I. Simon, Y. Gao, C. Cai, H. Yang, et
al. 2016. “Protein phosphatase 1 suppresses androgen receptor
ubiquitylation and degradation.” Oncotarget 7 (2): 1754-1764.
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:26860114
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Oncotarget1754www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 2
Protein phosphatase 1 suppresses androgen receptor ubiquitylation 
and degradation
Xiaming Liu1,*, Weiwei Han2,*, Sarah Gulla1, Nicholas I. Simon1, Yanfei Gao1, 
Changmeng Cai1, Hongmei Yang3, Xiaoping Zhang2, Jihong Liu4, Steven P. Balk1, 
Shaoyong Chen1
1 Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, 
Boston, Massachusetts 02215, USA
2 Department of Urology, Union Hospital, Tongji Medical School, Huazhong University of Science and Technology, Wuhan 
430022, China
3 Department of Pathogen Biology, Tongji Medical School, Huazhong University of Science and Technology, Wuhan 430030, 
China
4Department of Urology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China
*These authors have contributed equally to this work
Correspondence to: Shaoyong Chen, e-mail: schen@bidmc.harvard.edu
Steven P. Balk, e-mail: sbalk@bidmc.harvard.edu
Keywords: androgen receptor, prostate cancer, protein phosphatase 1
Received: August 06, 2015     Accepted: November 18, 2015     Published: November 30, 2015
ABSTRACT
The phosphoprotein phosphatases are emerging as important androgen receptor 
(AR) regulators in prostate cancer (PCa). We reported previously that the protein 
phosphatase 1 catalytic subunit (PP1α) can enhance AR activity by dephosphorylating 
a site in the AR hinge region (Ser650) and thereby decrease AR nuclear export. In this 
study we show that PP1α increases the expression of wildtype as well as an S650A 
mutant AR, indicating that it is acting through one or more additional mechanisms. We 
next show that PP1α binds primarily to the AR ligand binding domain and decreases its 
ubiquitylation and degradation. Moreover, we find that the PP1α inhibitor tautomycin 
increases phosphorylation of AR ubiquitin ligases including SKP2 and MDM2 at sites 
that enhance their activity, providing a mechanism by which PP1α may suppress AR 
degradation. Significantly, the tautomycin mediated decrease in AR expression was 
most pronounced at low androgen levels or in the presence of the AR antagonist 
enzalutamide. Consistent with this finding, the sensitivity of LNCaP and C4–2 PCa 
cells to tautomycin, as assessed by PSA synthesis and proliferation, was enhanced 
at low androgen levels or by treatment with enzalutamide. Together these results 
indicate that PP1α may contribute to stabilizing AR protein after androgen deprivation 
therapies, and that targeting PP1α or the AR-PP1α interaction may be effective in 
castration-resistant prostate cancer (CRPC).
INTRODUCTION
The androgen receptor (AR) plays a central role 
in prostate cancer (PCa) development and progression. 
Most patients initially respond to androgen deprivation 
therapy (ADT, surgical or medical castration), but 
the tumors inevitably recur despite castrate levels of 
androgen (castration-resistant prostate cancer, CRPC). 
AR expression is generally increased in CRPC, and one 
mechanism driving its activity is intratumoral synthesis 
of androgens from adrenal gland derived precursors 
or de novo from cholesterol [1–4]. This activity can be 
suppressed by drugs including abiraterone (which inhibits 
the enzyme CYP17A1 required for androgen synthesis) 
or by the direct AR antagonist enzalutamide, and both 
abiraterone and enzalutamide are now approved for 
treatment of CRPC [5, 6]. However, patients who respond 
to these agents generally relapse within a year, and AR 
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appears to still be contributing to the growth of these 
relapsed tumors [7, 8]. Therefore, there remains a critical 
need to identify further mechanisms contributing to AR 
activity.
AR mRNA is highly expressed in CRPC with the 
AR gene being amplified in many cases [9, 10], while 
epigenetic mechanisms can further enhance AR gene 
transcription [11, 12]. AR activity in CRPC also may 
be enhanced by multiple kinase signaling pathways that 
directly or indirectly increase AR protein stability or 
transcriptional activity at low androgen levels [13, 14]. 
Recent findings have also underscored the significance 
of protein phosphatases in regulating AR and in PCa 
development. Protein phosphatase 2A (PP2A) can bind 
to AR and suppress its activity by dephosphorylation 
of several sites [15, 16]. The physiological relevance 
of PP2A in PCa development is supported by the 
identification of alterations in PP2A and its subunits in 
PCa model systems and clinical specimens during tumor 
progression [17–19]. In contrast to PP2A, we reported 
that the protein phosphatase 1 catalytic subunit (PP1α) 
can enhance AR activity by dephosphorylating a site 
in the hinge region, Ser650 [16]. Phosphorylation of 
this site was shown previously to enhance AR nuclear 
export [20], and we found that PP1α inhibition decreased 
nuclear expression of wild-type AR, but not an S650A 
mutant AR [16].
In this study we show that PP1α can also 
increase AR expression independently of S650 
dephosphorylation. We find that PP1α binds to the AR 
ligand binding domain and decreases AR ubiquitination 
and degradation, particularly at low androgen levels or 
in the presence of AR antagonists. Mechanistically, we 
show that PP1α can dephosphorylate and inactivate 
ubiquitin ligases that target AR for ubiquitylation and 
degradation. Together these findings show that PP1α 
can contribute to maintaining AR protein expression 
and activity in CRPC, and that targeting PP1α or the 
AR-PP1α interaction may be a novel therapeutic 
approach.
RESULTS
PP1α can enhance AR activity independently of 
S650 phosphorylation site
Phosphorylation of AR at S650 enhances its 
nuclear export and subsequent degradation [20]. We 
reported previously that PP1α interacts with AR and 
dephosphorylates S650, thereby increasing nuclear 
AR in PCa cells [16]. In support of this conclusion, we 
showed that PP1α inhibition with tautomycin decreased 
nuclear levels of the wild-type AR, but not an S650A 
mutant AR. However, in further studies we have found 
that PP1α overexpression enhances the transcriptional 
activity of both the wild-type and S650A mutant AR, 
as assessed by co-transfection of AR, PP1α and an AR 
regulated reporter gene into HeLa cells or LNCaP PCa 
cells (Figure 1A). Moreover, the effects of PP1α on the 
wild-type and S650A mutant AR were comparable, with 
the S650A having slightly more basal activity in the 
absence of cotransfected PP1α (Figure 1B). To discount 
effects from endogenous AR in LNCaP cells, we also 
examined the role of S650 in a W741C mutant AR, 
for which bicalutamide acts as an agonist versus being 
an antagonist for wild-type AR [21]. Significantly, the 
bicalutamide stimulated activities of both the W741C 
and W741C/S650A double mutant ARs in LNCaP 
cells were similarly increased by PP1α co-transfection 
(Figure 1C).
Together these results indicated that PP1α 
may regulate AR activity by one or more additional 
S650 independent mechanisms. Consistent with our 
previous report [16], PP1α overexpression in transient 
transfections increases AR protein (Figure 1D), and 
this increase could be prevented by treatment with the 
PP1α inhibitor tautomycin (Supplementary Figure 
S1). While tautomycin at comparable concentrations 
can also inhibit PP2A, we showed previously that 
PP2A increases AR degradation and that the PP2A-
specific inhibitor fostriecin increases AR protein [16] 
(see also Supplementary Figure 2). PP1α inhibition 
with tautomycin also decreased endogenous AR 
protein in both LNCaP and C4–2 cells, particularly in 
steroid-depleted medium without addition of androgen 
(dihydrotestosterone, DHT) (Figure 1E). Significantly, 
tautomycin similarly decreased expression of the 
transiently transfected S650A mutant AR in HeLa cells 
(Figure 1F), and the stably expressed S650A mutant AR 
in LNCaP cells (Figure 1G, and Supplementary Figure 
S3). In both cases this effect was most pronounced in 
steroid-depleted medium in the absence of exogenous 
DHT. These results show that one mechanism through 
which PP1α can increase AR activity independently of 
S650 dephosphorylation is by increasing AR protein.
Consensus PP1α-interacting KVFF motif in AR 
DNA binding domain is not essential for binding
As PP1α and AR can form a complex [16], 
we next focused on the identification of molecular 
determinants mediating the PP1α-AR interaction 
and their role in increasing AR protein. PP1α has 
two consensus docking motifs shared by interacting 
partners, R/K-x(0,1)-V-x-F and F-x-x-R/K-x-R/K, 
where x stands for any amino acid [22]. AR has one 
potential PP1α binding motif, KVFF, locating in the 
DNA-binding domain (DBD) and in the vicinity of 
the zinc finger 1 that mediates DNA binding (Figure 
2A). Interestingly, all class I steroid receptors (AR/GR/
PR/MR) except ERα possess this motif. Moreover, we 
found that PP1α cotransfection could also enhance the 
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transcriptional activity of GR and MR, but not ERα, 
suggesting a possible role for this site in mediating 
an interaction with PP1α (Supplementary Figure S4). 
Consistent with the essential function of this site for 
DNA binding, disruption of this motif by mutagenesis 
(KVFF to KAFA) resulted in complete transcriptional 
inactivation of AR (Figure 2B).
We then took a coimmunoprecipitation approach 
to assess for a role of this candidate motif in the 
AR-PP1α interaction. As shown in figure 2C, wild-
type and KAFA mutant AR pulled down comparable 
amounts of PP1α in both 293T and Cos1 cell lines. As 
a complementary approach, we also used microcystin-
agarose beads to precipitate endogenous PP1α and to 
assess its interaction with AR [16]. The results showed 
that in HeLa cells PP1α associates both with the wild-
type and the KAFA mutant AR (Figure 2D). To further 
substantiate the above findings, we next generated an 
AR-DBD fragment and its mutated counterpart (DBD-
KAFA) and assessed binding to PP1α. The results 
indicated that PP1α may interact with the AR-DBD, 
but that this interaction was not mediated by the KVFF 
motif (Figure 2E). Together, these results indicated that 
the KVFF site plays minimal if any role in PP1α-AR 
interaction.
PP1α interacts predominantly with the AR 
ligand-binding domain
We next systematically assessed the association 
between PP1α and a panel of constructs spanning 
the AR N-terminal domain (NTD) that bears the 
major transcriptional activation function, the central 
DNA-binding domain (DBD), and the C-terminal 
ligand-binding domain (LBD). Analysis in androgen-
containing medium demonstrated that PP1α could 
associate with the isolated NTD and LBD, with the 
inclusion of the DBD not causing an appreciable 
increase in binding (Figure 3A). Comparison with the 
inputs further indicates that PP1α has higher affinity 
Figure 1: PP1α can stabilize and activate AR independently of phospho-S650 dephosphorylation. A. HeLa and LNCaP 
cells were co-transfected with AR-S650A mutant and PP1α, together with ARE4-Luc reporter and CMV-Renilla (internal control). The 
cells were then incubated for overnight in androgen-depleted medium with DHT (10 nM) for dual-Luc analyses. B. LNCaP cells were 
co-transfected with Renilla (internal control) and ARE4-Luc reporters, together without or with AR wild-type (WT) versus AR-S650A 
mutant and PP1 catalytic subunit (PP1α). The cells were treated for overnight with androgens (10 nM of DHT) for Dual-Luc analysis. C. 
LNCaP cells in androgen-depleted medium were co-transfected with Renilla and ARE4-Luc reporters, together with AR-W741C construct 
versus AR-W741C-S650A mutant and PP1α as indicated. The cells were then incubated for overnight in androgen-depleted medium with 
bicalutamide (BIC, 10 μM) as indicated for Dual-Luc analysis. D. HeLa cells were transfected with Flag-PP1α and HA-AR and then 
incubated for overnight in androgen-depleted medium without or with androgen (10 nM of DHT) as indicated for blotting. E. LNCaP 
and C4–2 cells in androgen-depleted medium were treated overnight with tautomycin (Tau, 100, 200, and 400 nM) and androgen (10 nM 
DHT for LNCaP and 1 nM DHT for C4–2) as indicated and proteins were normalized for blotting. F,G. HeLa cells were transfected with 
AR S650A mutant (F) and a LNCaP line was generated to stably express Flag-tagged AR-S650A construct (G) Cells in androgen-depleted 
medium were treated for indicated time points with androgen (10 nM of DHT) and tautomycin (Tau, 400 nM) and proteins were normalized 
for blotting.
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for the AR LBD than the NTD. We similarly observed 
preferential binding to the AR LBD when cells were 
cultured in steroid-depleted medium (Figure 3B). It 
should be noted while AR is primarily cytoplasmic in 
the absence of ligand and accumulates in the nucleus 
in response to androgen, PP1α is highly expressed in 
the nucleus and cytoplasm (Supplementary Figure S5). 
Therefore, cellular localization is less likely to be a 
major factor dictating the association between PP1α and 
these AR domains.
Notably, the PP1α-associated AR migrated on the 
gels as a major band with a series of distinct minor bands 
separated by ~8 KDa, consistent with ubiquitylation. To 
confirm that these bands were ubiquitylated AR, we co-
expressed histidine-tagged ubiquitin (his-Ub) together with 
PP1α and AR, and then used Nickel(Ni)-NTA resin under 
denaturing conditions to pull-down ubiquitylated proteins. 
Immunoblotting for the HA-tagged AR then revealed 
higher molecular weight bands indicative of ubiquitylation 
associated primarily with constructs containing the LBD 
(Figure 3C). It should be noted that we also observed bands 
whose migration was consistent with the unmodified DBD-
LBD or LBD fragments (see also Supplementary Figure S6), 
which we presume reflect weak nonspecific binding to the 
resin compared to the ubiquitylated proteins that were highly 
enriched by the resin. We observed a similar pattern in the 
absence of transfected PP1α, consistent with the AR LBD 
being the primary target for ubiquitylation (Figure 3D).
PP1α stabilizes AR by decreasing AR LBD 
polyubiquitylation
The above findings suggested that PP1α may 
stabilize AR protein by decreasing ubiquitylation of the 
LBD. To examine this further, we assessed effects of 
PP1α overexpression and proteasome inhibitor (MG132) 
treatment on ubiquitylation of the AR LBD. In the 
absence of transfected PP1α, treatment with MG132 
increased both the levels of oligo- and poly-ubiquitylated 
AR LBD (Figure 4A). In contrast, these ubiquitylated 
AR species, and in particular the polyubiquitylated AR, 
were not increased by MG132 in cells cotransfected with 
PP1α. Cotransfection of PP1α similarly decreased the 
polyubiquitylation of full length AR (Figure 4B).
To determine whether this PP1α mediated decrease 
in AR polyubiquitylation resulted in decreased AR 
degradation, we next used cycloheximide to block new 
protein synthesis and thereby assess AR protein stability. 
PP1α cotransfection markedly decreased degradation of 
full length AR (Figure 4C). Moreover, consistent with 
PP1α suppressing polyubiquitylation of the AR LBD, 
PP1α cotransfection also markedly increased stability 
Figure 2: The potential PP1α-interacting KVFF motif of AR is not essential for AR-PP1α interaction. A. A schematic 
drawing shows the linear amino acid sequence alignment of the zinc finger regions in the DNA binding domains of the class-I steroid 
receptors. Highlighted in the frame is the unique PP1α-interacting consensus motif (KVxF) that exists in AR, GR, PR, and MR, but not 
ERα. Amino acid sequences are based on human androgen receptor (AR; GenBank M20132.1); human glucocorticoid receptor (GRα; 
NM_001018077); human progesterone receptor (PR; M15716.1); human mineralocorticoid receptor (MR, NM_000901.3); and human 
estrogen receptor (ERα; NM_000125.3). B. AR-deficient PCa cell line (PC3) was transfected with AR-mediated probasin-Luc and CMV-
Renilla reporters, together with AR wild-type (WT) versus KVFF mutant (KVFF to KAFA). Cells were then incubated for overnight in 
androgen-depleted medium with 10 nM of DHT for Dual-Luc analysis. C. 293T and Cos1 cells were co-transfected with PP1α and Flag-
tagged AR wild-type versus KVFF mutant (KAFA), with the empty Flag vector (−) as control. Co-immunoprecipitation (Co-IP) assay was 
carried out using anti-Flag-M2 beads. D. HeLa cells transfected with AR wild-type versus KAFA mutant were incubated for overnight in 
androgen-depleted medium with 10 nM of DHT, followed by microcystin (MC)-IP and blotting. E. Flag-tagged PP1α was co-transfected in 
293T cells with HA tagged AR-DBD wild-type (WT) versus DBD mutant (KAFA) constructs, followed by Co-IP using anti-Flag-M2 beads 
and blotting. Flag or HA empty vectors (−) were used as controls, respectively. Non-specific IgG bands are marked (*).
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of the AR LBD, but not the AR NTD-DBD fragment 
(Figure 4C). Finally, PP1α with an H248K mutation that 
inactivates its phosphatase activity was unable to increase 
AR protein, indicating that PP1α stabilizes AR through 
dephosphorylation of one or more substrates (Figure 4D).
PP1α dephosphorylates ubiquitin ligases 
mediating AR degradation
Several ubiquitin ligases, including MDM2 
and SKP2, have been implicated as mediators of 
AR ubiquitylation and degradation [23–26]. MDM2 
degradation can be enhanced by phosphorylation at 
multiple sites including S395, and previous reports 
indicate that PP1α can decrease the degradation of MDM2 
by dephosphorylating this site [27]. However, MDM2 
activity can also be enhanced by growth factor stimulated 
phosphorylation of sites including S166 and S186 [28]. 
Effects of PP1α on SKP2 have not been addressed 
previously. Therefore, we next assessed whether PP1α 
may dephosphorylate and inactivate these ubiquitin ligases 
to attenuate AR ubiquitylation and degradation.
Consistent with previous reports, AR protein 
expression was decreased by cotransfection of MDM2 
Figure 3: PP1α engages predominantly with the AR ligand-binding domain (LBD) that is enriched in ubiquitination. A. 
293T cells in medium containing 5% FBS were transfected with Flag-tagged PP1α (Flag-PP1α) and HA-tagged AR full length (HA-AR FL) 
versus additional AR constructs (N: NTD; N-D: NTD-DBD; D: DBD; D-L: DBD-LBD; and L: LBD), followed by anti-Flag co-IP analysis 
for blotting. Arrows indicate native AR bands and non-specific IgG bands are marked (*). Flag-tagged Sox9, which weakly interacts with AR, 
was used as control. B. Similarly, 293T cells were transfected with Flag-PP1α and HA-AR full length versus NTD-DBD and LBD constructs. 
After transfection, cells were then incubated for overnight in androgen-depleted medium for co-IP and blotting. C. 293T cells in androgen-
depleted medium were transfected with His-Ub, Flag-PP1α, and HA-AR constructs as indicated, followed by Ni(nickel)-NTA-IP under 
denatured condition and blotted. D. Similarly, 293T cells in androgen-depleted medium were transfected with His-Ub and indicated HA-AR 
constructs, followed by Ni-NTA-IP under denatured conditions. Arrowheads in the upper panels mark positions of the native AR constructs 
and an arrowhead on the lower panel of (C) marks the mono-ubiquitylated PP1α. Mr: Molecular weight marker in Kilodalton (KDa).
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or SKP2 (Figure 5A). Cotransfection of PP1α resulted 
in a dramatic increase in the levels of transfected 
MDM2 and SKP2, which appears to be primarily 
due to increased transcription and translation from 
the expression vectors rather than decreased protein 
degradation. However, this may also in part reflect PP1α 
mediated inactivation of MDM2 and SKP2 enzymatic 
activities, as this would suppress autoubiquitylation 
and degradation [29, 30]. In either case, despite the 
dramatic increases in MDM2 and SKP2, there were no 
increases in the ability of these proteins to suppress AR 
expression, indicating that their activity was markedly 
impaired by PP1α (Figure 5A).
To determine whether endogenous PP1α may 
regulate the phosphorylation and activity of these 
ubiquitin ligases, we treated HeLa and LNCaP 
cells with tautomycin and assessed for effects on 
endogenous MDM2 and SKP2. We did not observe 
clear increases in MDM2 or SKP2 in either cell line 
(Figure 5B). However, tautomycin increased MDM2 
phosphorylation at S166, which has been reported to 
enhance MDM2 activity [28]. Similarly, tautomycin 
increased SKP2 phosphorylation at S72, a site that 
may be phosphorylated by AKT and lead to increased 
stability and activity [31, 32]. Consistent with increased 
activity of MDM2 and SKP2, tautomycin treatment 
decreased levels of their respective substrates, p53 and 
p27 (Figure 5C).
Taken together these findings indicated that 
PP1α inhibition may increase AR ubiquitylation and 
degradation by increasing the activity of one or more 
AR degrading ubiquitin ligases. However, it was not 
clear whether or how these effects on MDM2 of SKP2 
were related to the PP1α-AR interaction. Therefore, 
we next asked whether AR could function as a scaffold 
to bridge PP1α and MDM2 or SKP2. HeLa cells were 
transfected with Flag-tagged PP1α and MDM2 or 
SKP2, with or without cotransfected AR. Anti-Flag 
immunoprecipitation then indicated that the PP1α-SKP2 
association was substantially increased by cotransfected 
Figure 4: PP1α stabilizes AR by attenuating LBD-directed AR ubiquitylation. A. 293T cells transfected with His-Ub, HA-
AR-LBD and Flag-PP1α were incubated overnight in androgen-depleted medium without or with MG132 (10 μM) as indicated, followed 
by Ni-NTA-IP under denatured conditions and blotting. SE: short exposure; LE: long exposure. B. 293T cells were transfected with HA-
Ub, Flag-AR-full-length together without or with PP1α. Cells were then incubated overnight in androgen-depleted medium, followed by 
anti-Flag-IP under denatured conditions. Mr: Molecular weight marker in Kilodalton (KDa). C. HeLa cells in androgen-depleted medium 
were co-transfected with HA-AR full-length (FL), NTD-DBD and LBD constructs, without or with Flag-PP1α and cycloheximide as 
indicated. Total proteins were harvested and normalized for blotting. D. HeLa cells in androgen-depleted medium were co-transfected with 
AR and PP1α wild-type versus its enzymatically inactive counterpart (H248K). Cells were then incubated in androgen-depleted medium 
for blotting.
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AR, consistent with a scaffold function (Figure 5D). 
AR cotransfection similarly increased the level of 
MDM2 that was coprecipitated with PP1α, but AR also 
increased input levels of MDM2, making interpretation 
of the result less clear (Figure 5D). Further studies to 
address this issue are now focused on identification of 
site directed mutations that can selectively impair the 
AR-PP1α interaction.
Androgen deprivation and AR antagonists 
sensitize PCa cells to PP1α inhibition
As noted in Figure 1, effects of tautomycin on 
AR protein expression in LNCaP and C4–2 cells were 
most marked under conditions of androgen deprivation. 
Therefore, we compared the effects of tautomycin in 
C4–2 cells cultured in androgen depleted medium 
without or with added DHT. Consistent with its effects 
on AR protein under these conditions, tautomycin 
was more potent at reducing expression of PSA and 
proliferation under androgen depleted conditions 
(Figure 6A).
Significantly, effects of tautomycin on AR protein 
expression in LNCaP and C4–2 cells were also enhanced 
by treatment with the AR antagonist enzalutamide 
(Figure 6B). Therefore, we examined the effects of 
tautomycin on AR activity in LNCaP and C4–2 cells 
without and with enzalutamide. In both cell lines, the 
inhibitory effects of tautomycin were enhanced by 
enzalutamide (Figure 6C). Collectively these findings 
indicate that agents targeting PP1α may enhance the 
efficacy of androgen deprivation therapies and be 
effective in CRPC.
DISCUSSION
AR undergoes basal and ligand stimulated 
phosphorylation at multiple sites, and these modifications 
can modulate it stability, cellular localization and 
transcriptional activity. AR phosphorylation may also 
be regulated by protein phosphatases, including PP2A 
and PP1. PP2A can dephosphorylate multiple sites in 
the AR N-terminal domain, including S81, S94, S258, 
S308, and S424, that are normally increased in response 
to androgen and are associated with increased AR 
transcriptional activity [15]. Significantly, PP2A access 
to these sites may be negatively regulated by androgen 
binding, indicating that a physiological function of PP2A 
may be to suppress basal AR activation in the absence of 
androgen [33].
Figure 5: PP1α can dephosphorylate AR degrading E3 ligases. A. HeLa cells were co-transfected with HA-AR, Flag-PP1α and 
HA-tagged MDM2 or SKP2 as indicated. Cells were then incubated for overnight in androgen-depleted medium for blotting. B. HeLa 
and LNCaP cells in androgen-depleted medium were treated for 3 hrs with 200 nM of tautomycin, followed by protein normalization for 
blotting. C. LNCaP cells in androgen-depleted medium were treated for 3 hrs with tautomycin as indicated. Total proteins were normalized 
for blotting. D. HeLa cells were transfected of Flag-PP1 and HA-MDM2 (left panel) or SKP2 (right panel), without or with AR as indicated. 
Cells were then incubated for overnight in androgen-depleted medium, followed by anti-Flag Co-IP and blotting.
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In contrast to PP2A, we had previously shown that 
PP1α could bind to AR and dephosphorylate AR at S650 
in the hinge region and thereby suppress AR nuclear 
export, providing a mechanism by which PP1α can 
enhance AR activity [7]. In the current study we found 
that PP1α could also suppress the polyubiquitylation of 
the AR LBD and its subsequent degradation, and that 
PP1α inhibition with tautomycin could thereby decrease 
AR expression independently of S650 dephosphorylation. 
Mechanistically, we found that PP1α inhibition with 
tautomycin increased the phosphorylation of MDM2 
and SKP2 at sites that could enhance their activities, 
suggesting that PP1α may suppress AR ubiquitylation by 
dephosphorylating these sites. Further results indicated 
that AR may mediate an interaction between PP1α and 
these ubiquitin ligases, but further studies are needed 
to determine the relationship between the AR-PP1α 
association and PP1α mediated dephosphorylation of 
MDM2, SKP2, and potentially other ubiquitin ligases.
This study also found that PP1α binding to AR is 
mediated primarily by the AR LBD. Although the precise 
site on the LBD remains to be determined, it does not 
appear to be the coactivator binding site as binding is not 
ligand dependent. We also cannot rule out that binding 
is indirect and mediated by a not yet identified PP1 
regulatory protein. An attractive hypothesis is that PP1α 
associated with the AR LBD directly protects AR from 
ubiquitylation by locally inactivating ubiquitin ligases. 
Alternatively, PP1α may more globally suppress a subset 
of ubiquitin ligases, with the AR associated PP1α having 
distinct functions including the dephosphorylation 
of S650. Further studies are underway to test these 
hypotheses.
In any case, these findings indicate that therapies 
targeting PP1α, or possibly the AR-PP1α interaction, 
may have efficacy in CRPC. Significantly, the decrease 
in AR protein in response to tautomycin was most 
dramatic under androgen depleted conditions and in cells 
treated with the AR antagonist enzalutamide. Therefore, 
PP1α activity may play a particularly important role in 
maintaining AR expression in CRPC and in resistance to 
enzalutamide.
Figure 6: Androgen ablation increases PP1α-dependence for AR protein expression and transactivation in PCa cells. A. 
C4–2 cells in androgen-depleted medium were treated with tautomycin and androgen (1nM DHT) for qRT-PCR analysis of PSA expression 
(24 hr treatment) or for cell proliferation (3-day treatment), with the results being normalized to the no tautomycin levels in the absence 
and presence of DHT. Veh: vehicle; DHT: 1 nM of DHT. B, C. LNCaP and C4–2 cells in androgen-containing medium (10% FBS) were 
treated with enzalutamide (ENZ, 10 μM) and tautomycin (100, 200, and 400 nM) as indicated. Total proteins (for 24 hr treatment) were 
harvested and normalized for blotting (B) and total RNA (for 24 hr treatment) was isolated for qRT-PCR analysis of PSA expression (C). 
The cell proliferation analysis was carried out after 3-day treatment (C). The gene expression and cell growth results were normalized to no 
tautomycin in the absence and presence of enzalutamide (C). Veh: vehicle; Enz: 10 μM of enzalutamide.
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MATERIALS AND METHODS
Materials
Anti-Flag M2 affinity gel was from Sigma-Aldrich, 
tautomycin and fostriecin were from Calbiochem and 
Enzo Life Science, Ni-NTA agarose was from Qiagen, 
and microcystin-agarose was from EMD Millipore. Anti-
AR, anti-PP1, anti-HA, anti-p27, and anti-p53 antibodies 
were from Cell Signaling, anti-β-Actin was from Abcam, 
anti-β-tubulin was from EMD Millipore, and anti-flag-M2 
was from Sigma-Aldrich. The anti-SKP2 (Santa Cruz) and 
anti-p-SKP2-S72 (Cell Signaling) antibodies were kindly 
provided by Dr. Inuzuka Hiroyuki, and the anti-MDM2 
and anti-p-MDM2-S166 (Santa Cruz) antibodies were 
kindly provided by Dr. Ming Chen (BIDMC, Harvard 
Medical School, Boston, USA). FBS and CDS (charcoal-
dextran stripped serum) were from Hyclone.
Immunoprecipitations (IPs)
For coimmunoprecipitation (co-IP), cells were 
harvested in triton lysis buffer (TLB) containing protease 
inhibitors. The lysates were incubated on ice for 20 min 
and centrifuged for 5 min at maximum speed. 20 μl of the 
supernatant was saved as input and the rest was incubated 
with anti-Flag beads, followed by incubation at 4°C on 
a rotator for 2 hr. Then the input and washed (4x) IP 
beads were boiled in 60 μl of Laemmli buffer containing 
5% β-mercaptoethanol. For immunoprecipitation (IP) 
under denatured conditions, cells were harvested by 
boiling in 2% SDS followed by 20x dilution the TLB. 
The test then proceeded as the above regular IP. For the 
ubiquitylation and Ni(nickel)-NTA-IP assay, the cells were 
washed in PBS and an aliquot was lysed in RIPA buffer 
as input. The rest was lysed in buffer A (6M guanidine 
HCl, 0.1 M Na2HPO4/NaH2PO4, 10 mM imidazole, 
pH 8.0), followed by sonication and centrifugation. The 
supernatants were incubated with Ni-NTA beads at room 
temperature for 3 hrs, followed by wash 2x with buffer A, 
2x with buffer A/buffer TI (1:3), and 1x with buffer TI (25 
mM Tris-Cl, 20 mM imidazole, pH 6.8). Then both input 
and the IP yields were boiled in 60 μl of Laemmli buffer 
containing 5% β-mercaptoethanol. Microcystin-IP was as 
previously described [16].
Gene expression analysis
RNA isolation was carried out using the TriZOL 
reagent and the qRT-PCR analysis on gene expression 
was performed with the TaqMan One-Step RT-PCR 
Master Mix Reagents (Applied Biosystems). The TaqMan 
primer and probe sets for gene expression assay: PSA: 
Forward, 5′- GATGAAACAGGCTGTGCCG-3′; Reverse, 
5′- CCTCACAGCTACCCACTGCA-3′; Probe, 5′- FAM-
CAGGAACAAAAGCGTGATCTTGCTGGG-3′. The 
TaqMan primer-probe set for GAPDH transcripts (internal 
control) was purchased as inventoried mix from Applied 
Biosystems.
Cell culture, cellular fractionation, transient 
transfection and reporter gene assays
LNCaP cells were grown in the RPMI-1640 medium 
and C4–2 and VCaP cells in DMEM medium containing 
10% FBS. PC3, 293T, HeLa, and Cos1 cells were grown 
in DMEM medium with 5% FBS. For androgen-starved 
conditions, cells were grown in medium containing 5% 
CDS. Cellular fractionation assay were carried out with 
the NE-PER kit (Pierce), following the manufacture’s 
direction. For transfection, cells were grown in normal 
growth medium to ~80% confluence and plasmid DNA 
was transfected with LipofectAMINE 2000. Empty 
relevant vectors (such as pCDNA3.1, HA vector, and Flag 
vector) were supplemented to equalize the total amount of 
plasmids in the transfections. After overnight transfection, 
the cultures were refreshed with indicated medium for 
treatments. The pCMV-pRL-Renilla and androgen-
responsive reporter plasmids have been described 
previously [16]. Additional steroids, steroids receptors 
and reporters were from the Balk lab. Luciferase activities 
were measured with the Dual-Luc assay kit (Promega). The 
ratios between Firefly and Renilla luciferase activities are 
shown as relative light units (RLU), and the results reflect 
the mean and standard deviation from triplicate samples.
Cell proliferation assay
Cells were cultured in 96-well plates for 2 days and 
then treated for 3 days as indicated. The cell proliferation 
analysis was performed with the CellTiter-Glo assay kit 
(Promega), following the manufacture’s manual.
Western blot data processing
The Western blotting was developed based on 
X-Ray film (Research Products International) and the 
western lightning Plus-ECL reagent (PerkinElmer). The 
images were acquired using the CanoScan LiDE 210 
scanner and processed using the Adobe Photoshop 7.0 
software. Relevant images were quantified by using the 
ImageJ software. All gels shown are representative of 
results from at least three experiments.
Plasmids and DNA mutagenesis
The AR constructs were generated based on the 
pcDNA3.1(+)-Kozak-HA-HA vector and cover the 
following regions: HA-HA-AR full-length (aa 1–919); 
HA-HA-AR-NTD (aa 1–539); HA-HA-AR-NTD-DBD 
(aa 1–628); HA-HA-AR-DBD (aa 538–628); and HA-
HA-AR-DBD-LBD (aa 538–919). The HA-AR-LBD 
(aa 662–919) vector was from our Lab. The untagged 
PP1α plasmid was from Origene and then cloned into the 
Oncotarget1763www.impactjournals.com/oncotarget
3x-Flag-CMV-10 vector (Sigma-Aldrich) to generate the 
Flag-PP1α expression plasmid. The his-Ub, Flag-Ub, Flag-
Sox9, HA-MDM2 and HA-SKP2 expression plasmids 
were kindly provided by Drs. Pengda Liu, Wenjian Gan, 
Xin Yuan, and Inuzuka Hiroyuki (BIDMC), respectively. 
DNA mutagenesis on AR and PP1α was performed 
with the Quick-change site-directed mutagenesis Kit 
(Stratagene). Details for plasmids and mutants generation 
are available upon request.
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